levotofisopam
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01519687)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Monoamine oxidaseINHIBITOR
Monoamine oxidase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H]1C(C)=NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc21- Mol. weight
- 382.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107351 ↗
Also known as
- levotofisopam
- levotofisopam
- levotofisopam
- levotofisopam
- (s)-tofisopam
- (s)-tofisopam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01519687 | Phase 2 | Jan 1, 2012 | Duke University, Pharmos |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Pharmos | For profit | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1